Table 1. Summary of Included Acute Rhinosinusitis Studies

First Author (Year)	Sample size(T/C);Sex(F/M); Age(Mean±SD yrs); Duration of disease	Treatment group	Control group	Outcome Measures	Period	Adverse events
马敏 (2005)5)	73(38/35); 32/41; 45; 9-16d	1.erythromycin (oral, 0.375g, tid)2.Dibiling (nasal drop, tid)	1.erythromycin (oral, 0.375g, tid)2.furacilin-ephedrine mixture(nasal drop)	1.Effective rate(%)2.MTT(min)	10d	NR
纪小美 (2011)6)	60(30/30);T: NR; 34.60±12.89; 4.4±1.99dC: NR; 35.27±14.41; 5±2.23d	1.Phellodendron nasal drop(tid) plus C	1.Biyuan tongqiao granule(oral, tid)2.azithromycin (oral, qd)	1.Effective rate(%)2.Main symptom score3.Secondary symptom score	10d	Mild irritaion in the nose NR
刘娇媚 (2019)7)	66(33/33);T:25/8; 35.27±9.69; NRC: 20/13;38.82±10.83; NR	1.Cang er zi san modified(steam inhalation) plus C	1.Cang er zi san modified(oral)	1.VAS2.SNOT-223.Lund-Kennedy4.Symptom score	14d	NR
邵亮 (2021)8)	90(47/47);T:18/29; 40.93±6.81; 15.99±2.90dC: 16/31; 41.74±6.55; 15.73±2.82d	1.Shufengqingre decoction(nasal spray, bid) plus C	1.nasal saline irrigation2.1% ephedrine nasal drop3.azithromycin (oral, 0.5g, qd)	1.Effective rate2.MTR3.Symptom score4.Improvement time	2wk	NR
袁艳红 (2023)9)	144(72/72);T:35/37; 34.1±4.3;7.7±1.1dC:33/39; 33.8±4.2;7.6±1.2d	1.cefuroxime (oral, 0.25g, bid)2.Biyuan granule (oral, 0.2g, tid)3.Bikangfu nasal tamponade(nasal administration, 5X a day)	1.cefuroxime (oral, 0.25g, bid)2.Biyuan granule (oral, 0.2g, tid)3.mometasone furoate (nasal spray, qd)	1.Effective rate2.Symptom score3.MCC(%), MTR(㎜/min)4.SNOT-205.Lund-Kennedy6.Levels of inflammatory factors in serum and nasal secretions	7d	Headache: T(0), C(5)Nosebleed: T(0), C(2)Sore throat: T(0), C(2)Diarrhea: T(1), C(1)Burning sense of nose: T(0), C(1)Nasal ulcer: T(0), C(1)
陈婕 (2023)10)	61(31/30);T:11/20; 7.48; NRC:8.22; 7.53; NR	1.Tongqiao Sanjie Recipe(ultrasonic nebulized inhalation, qd)	1.mometasone furoate(nasal spray, qd)	1.VAS2.Symptom score	5d	NR
黄扬周 (2023)11)	113(56/57);T:27/29; 7.72±1.71;4.25±1.27dC:30/27; 6.29±0.89;5.29±2.08d	1.Cang er zi san (steam inhalation, qd) plus C	1.amoxicillin (oral, bid)2.budesonide (nasal spray, bid)	1.Effective rate2.VAS3.MTT4.Lund-Kennedy	10d	NR

Abbreviations: T: treatment group; C: control group; F: female; M: male; yrs: years; d: days; tid: three times a day; MTT: mucociliary transport time; NR: not reported; qd: every day; SNOT: sino-nasal outcome test; MTR: mucociliary transport rate; bid: two times a day; wk: week; MCC: mucociliary clearance